Immunology Research & Development, CSL Behring, LLC, 1020 First Avenue, King of Prussia, PA 19406, USA and Pediatrics & Pathology, Case Western Reserve University, Cleveland, OH, USA.
Immunotherapy. 2014;6(1):71-83. doi: 10.2217/imt.13.146.
Subcutaneous administration of IgG (SCIG) has become widely used in primary immune deficiency diseases but it has only recently been studied for maintenance therapy in autoimmune peripheral neuropathies, such as chronic idiopathic demyelinating polyneuropathy and multifocal motor neuropathy. Weekly self-administration of SCIG is safe and well-tolerated, and results in steady-state serum IgG levels, as contrasted with the peaks and troughs of monthly immune globulin (human) for intravenous use. Freedom from the need for venous access or medical personnel for infusions, flexibility in scheduling, convenience of home therapy, and improved clinical stability due to the steady-state IgG levels, lead many patients to prefer SCIG to immune globulin (human) for intravenous use. Long-term studies are needed to determine if the constant IgG levels and clinical stability translate into better long-term outcomes.
皮下注射免疫球蛋白（SCIG）已广泛应用于原发性免疫缺陷病，但最近才开始研究其在自身免疫性周围神经病（如慢性特发性脱髓鞘性多发性神经病和多灶性运动神经病）中的维持治疗作用。每周自行皮下注射 SCIG 安全且耐受良好，可使血清 IgG 水平达到稳态，与每月静脉用人免疫球蛋白（human）的峰谷浓度形成对比。由于 IgG 水平达到稳态，患者无需静脉通路或医务人员输注，治疗安排更灵活，家庭治疗更方便，临床稳定性提高，许多患者更愿意选择 SCIG 而非静脉用人免疫球蛋白（human）。需要进行长期研究以确定 IgG 水平的持续稳定和临床稳定性是否转化为更好的长期结局。
